Soleus Capital Management, L.P.
Soleus Capital Management, L.P. reported 97 US-listed holdings worth $2.90 billion in its 13F for the quarter ended 30 June 2026, filed 11 August 2026. Its largest: Krystal Biotech, Inc. (12.0%), Celcuity Inc. (6.1%) and TG Therapeutics, Inc. (5.5%). Against the quarter before, it opened 22 positions, added to 25, trimmed 41 and sold out of 18.
Reported holdings$2.90B+17.5% on Q1 2026
Positions97+4 on Q1 2026
The largest ten48.9%of its reported holdings
Latest 13FQ2 2026filed 11 August 2026
Added toTrimmed
The 14 largest of its 97 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What it did on the quarter
Opened 22Added 25Held 9Trimmed 41Sold out 18
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 22
- Erasca Inc. ERAS$49.5 million
- Parabilis Medicines Inc. Com PBLS$40.1 million
- Legend Biotech Corp. LEGN$34.8 million
- UnitedHealth Group Inc. UNH$33.3 million
- Palisade Bio Inc. PALI$27.3 million
- Supernus Pharmaceuticals, Inc. SUPN$24.2 million
- Nuvectis Pharma Inc. NVCT$18.4 million
- Capricor Therapeutics Inc. CAPR$18.3 million
and 14 more in the table below
Added to 25
- Insulet Corp. PODD+486,500 shares · +86%
- Rigel Pharmaceuticals Inc. RIGL+1.8 million shares · +18335%
- Inspire Medical Systems, Inc. INSP+1.4 million shares · +235%
- Celcuity Inc. CELC+419,940 shares · +33%
- Avalo Therapeutics Inc. AVTX+1.2 million shares · +274%
- Arcus Biosciences, Inc. RCUS+716,755 shares · +159%
- United Therapeutics Corp. UTHR+38,400 shares · +21%
- Procept Biorobotics Corp. PRCT+843,000 shares · +527%
and 17 more in the table below
Trimmed 41
- Twist Bioscience Corp. TWST-1.1 million shares · -91%
- Krystal Biotech, Inc. KRYS-213,833 shares · -19%
- TG Therapeutics, Inc. TGTX-1.1 million shares · -27%
- Praxis Precision Medicines I PRAX-153,000 shares · -46%
- Alkermes plc. ALKS-941,612 shares · -48%
- Vericel Corp. VCEL-1.1 million shares · -43%
- Edgewise Therapeutics Inc. EWTX-999,026 shares · -69%
- Mirum Pharmaceuticals Inc. MIRM-325,306 shares · -81%
and 33 more in the table below
Sold out of 18
- Vaxcyte Inc. PCVX$22.4 million last quarter
- ICON plc ICLR$21.2 million last quarter
- Travere Therapeutics Inc. TVTX$16.2 million last quarter
- Inhibrx Biosciences Inc. INBX$8.8 million last quarter
- Dexcom Inc. DXCM$8.8 million last quarter
- Immunic Inc. IMUX$5.0 million last quarter
- Eton Pharmaceuticals Inc. ETON$4.1 million last quarter
- Arrowhead Pharmaceuticals, Inc. ARWR$1.8 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Krystal Biotech, Inc. KRYS | 939,254 | $349.1 million | 12.03% | -213,833 |
| Celcuity Inc. CELC | 1,704,318 | $178.3 million | 6.14% | +419,940 |
| TG Therapeutics, Inc. TGTX | 2,927,895 | $160.9 million | 5.54% | -1,101,424 |
| Insulet Corp. PODD | 1,049,000 | $159.7 million | 5.50% | +486,500 |
| Novocure Ltd NVCR | 9,913,401 | $150.2 million | 5.18% | -578,990 |
| United Therapeutics Corp. UTHR | 225,587 | $122.2 million | 4.21% | +38,400 |
| Inspire Medical Systems, Inc. INSP | 1,931,436 | $86.2 million | 2.97% | +1,355,137 |
| Rigel Pharmaceuticals Inc. RIGL | 1,843,504 | $72.1 million | 2.49% | +1,833,504 |
| ANI Pharmaceuticals Inc. ANIP | 867,760 | $71.8 million | 2.48% | +47,517 |
| Beta Bionics Inc BBNX | 4,393,714 | $68.8 million | 2.37% | +39,213 |
| Vericel Corp. VCEL | 1,459,152 | $64.9 million | 2.24% | -1,089,927 |
| Praxis Precision Medicines I PRAX | 177,517 | $59.4 million | 2.05% | -153,000 |
| Geron Corp. GERN | 42,808,659 | $54.8 million | 1.89% | +1,300,000 |
| Alkermes plc. ALKS | 1,029,252 | $53.9 million | 1.86% | -941,612 |
| Erasca Inc. ERAS | 2,700,000 | $49.5 million | 1.70% | new |
| Neuropace Inc. NPCE | 2,911,122 | $46.3 million | 1.59% | -21,085 |
| Progyny, Inc. PGNY | 1,602,000 | $46.2 million | 1.59% | -465,000 |
| Indivior Pharmaceuticals, Inc. INDV | 1,064,000 | $43.7 million | 1.50% | -210,000 |
| Parabilis Medicines Inc. Com PBLS | 1,465,070 | $40.1 million | 1.38% | new |
| Edap TMS S A FOCL | 7,309,254 | $37.9 million | 1.30% | no change |
| Globus Medical Inc. GMED | 468,922 | $37.0 million | 1.28% | -260,545 |
| Arcus Biosciences, Inc. RCUS | 1,168,738 | $36.0 million | 1.24% | +716,755 |
| Syndax Pharmaceuticals Inc. SNDX | 1,628,039 | $35.6 million | 1.23% | -98,869 |
| Nurix Therapeutics Inc. NRIX | 1,465,163 | $35.5 million | 1.22% | +527,000 |
| Legend Biotech Corp. LEGN | 1,205,000 | $34.8 million | 1.20% | new |
| Jade Biosciences Inc. JBIO | 1,550,690 | $34.5 million | 1.19% | +753,946 |
| UnitedHealth Group Inc. UNH | 80,000 | $33.3 million | 1.15% | new |
| Avalo Therapeutics Inc. AVTX | 1,654,978 | $30.6 million | 1.05% | +1,213,000 |
| Urogen Pharma Ltd URGN | 829,810 | $30.5 million | 1.05% | +102,810 |
| MBX Biosciences Inc. MBX | 515,279 | $28.4 million | 0.98% | +336,382 |
| Palisade Bio Inc. PALI | 13,063,687 | $27.3 million | 0.94% | new |
| Pharvaris N V PHVS | 730,907 | $25.3 million | 0.87% | +28,855 |
| Organogenesis Hldgs Inc. ORGO | 10,140,951 | $24.6 million | 0.85% | +55,000 |
| Supernus Pharmaceuticals, Inc. SUPN | 520,000 | $24.2 million | 0.83% | new |
| Procept Biorobotics Corp. PRCT | 1,003,000 | $22.6 million | 0.78% | +843,000 |
| Tango Therapeutics Inc. TNGX | 709,000 | $22.2 million | 0.76% | +259,000 |
| Inhibikase Therapeutics Inc. IKT | 10,875,000 | $22.1 million | 0.76% | no change |
| Trevi Therapeutics Inc. TRVI | 1,179,618 | $22.0 million | 0.76% | -440,382 |
| Biomarin Pharmaceutical Inc. BMRN | 375,572 | $21.5 million | 0.74% | -275,000 |
| LivaNova plc LIVN | 254,957 | $21.0 million | 0.72% | -327,543 |
| argenx SE ARGX | 19,955 | $18.5 million | 0.64% | +16,455 |
| Nuvectis Pharma Inc. NVCT | 1,000,000 | $18.4 million | 0.63% | new |
| Capricor Therapeutics Inc. CAPR | 761,737 | $18.3 million | 0.63% | new |
| Edgewise Therapeutics Inc. EWTX | 450,889 | $18.3 million | 0.63% | -999,026 |
| Prelude Therapeutics Inc. PRLD | 3,378,378 | $18.0 million | 0.62% | new |
| Xenon Pharmaceuticals Inc. XENE | 267,000 | $16.1 million | 0.56% | -25,000 |
| C4 Therapeutics Inc. CCCC | 3,377,981 | $15.8 million | 0.54% | -425,961 |
| Kiniksa Pharmaceuticals Intl KNSA | 246,353 | $15.8 million | 0.54% | -275,000 |
| Orthopediatrics Corp. KIDS | 732,144 | $14.0 million | 0.48% | +116,697 |
| Avalyn Pharma Inc. AVLN | 419,000 | $13.8 million | 0.48% | new |
| Biodesix Inc. BDSX | 585,958 | $13.2 million | 0.46% | +169,359 |
| Spyre Therapeutics Inc. SYRE | 147,000 | $13.1 million | 0.45% | new |
| Twist Bioscience Corp. TWST | 104,629 | $10.8 million | 0.37% | -1,122,000 |
| Vir Biotechnology, Inc. VIR | 1,000,000 | $10.2 million | 0.35% | -1,002,000 |
| Alnylam Pharmaceuticals Inc ALNY | 33,050 | $9.9 million | 0.34% | -98,600 |
| Immunovant Inc. IMVT | 252,000 | $9.7 million | 0.33% | +22,000 |
| Insmed Inc. INSM | 90,250 | $9.6 million | 0.33% | +80,000 |
| Septerna Inc. SEPN | 275,000 | $9.2 million | 0.32% | no change |
| Sophia Genetics SA SOPH | 1,565,000 | $9.0 million | 0.31% | -285,000 |
| Nektar Therapeutics NKTR | 128,362 | $9.0 million | 0.31% | new |
| Mirum Pharmaceuticals Inc. MIRM | 75,000 | $8.8 million | 0.30% | -325,306 |
| Artivion, Inc. AORT | 388,000 | $8.7 million | 0.30% | new |
| Tandem Diabetes Care Inc. TNDM | 575,000 | $8.7 million | 0.30% | -208,000 |
| Enliven Therapeutics Inc. ELVN | 165,677 | $8.4 million | 0.29% | -65,192 |
| Sionna Therapeutics Inc SION | 177,687 | $7.8 million | 0.27% | -115,813 |
| Belite Bio Inc. BLTE | 50,524 | $7.8 million | 0.27% | new |
| Cerus Corp. CERS | 2,500,000 | $7.3 million | 0.25% | -8,253,700 |
| Silence Therapeutics PLC SLN | 630,000 | $6.9 million | 0.24% | new |
| Immunic Inc. IMUX | 450,000 | $6.9 million | 0.24% | new |
| Invivyd Inc. IVVD | 7,708,727 | $6.7 million | 0.23% | no change |
| Merck & Co., Inc. MRK | 50,000 | $6.4 million | 0.22% | -153,000 |
| Relmada Therapeutics Inc. RLMD | 842,106 | $5.8 million | 0.20% | no change |
| Structure Therapeutics Inc. GPCR | 107,000 | $5.7 million | 0.20% | +27,000 |
| Evolus Inc. EOLS | 822,428 | $5.7 million | 0.20% | -1,422,932 |
| Adlai Nortye Ltd ANL | 405,523 | $4.7 million | 0.16% | new |
| Zentalis Pharmaceuticals Inc. ZNTL | 950,000 | $4.6 million | 0.16% | new |
| Karyopharm Therapeutics Inc. KPTI | 440,000 | $4.3 million | 0.15% | no change |
| Context Therapeutics Inc. CNTX | 7,063,141 | $3.9 million | 0.13% | +100,000 |
| Pulmonx Corp. LUNG | 2,788,323 | $3.6 million | 0.12% | no change |
| Sab Biotherapeutics Inc. SABS | 900,000 | $3.5 million | 0.12% | -150,000 |
| Tectonic Therapeutic Inc. TECX | 101,684 | $3.5 million | 0.12% | -20,000 |
| Axogen Inc. AXGN | 57,036 | $2.6 million | 0.09% | -622,134 |
| Satellos Bioscience Inc. MSLE | 314,359 | $2.4 million | 0.08% | -100,000 |
| Arrivent Biopharma Inc. AVBP | 50,000 | $1.7 million | 0.06% | new |
| Corcept Therapeutics Inc. CORT | 19,653 | $1.7 million | 0.06% | -265,878 |
| Solid Biosciences Inc. SLDB | 150,000 | $1.5 million | 0.05% | new |
| Veracyte, Inc. VCYT | 25,000 | $1.5 million | 0.05% | -294,912 |
| Cullinan Therapeutics Inc. CGEM | 50,000 | $910,500 | 0.03% | -360,200 |
| Inspiremd Inc. NSPR | 1,045,708 | $732,100 | 0.03% | no change |
| Genedx Holdings Corp. WGS | 10,000 | $686,500 | 0.02% | new |
| Iovance Biotherapeutics Inc. IOVA | 150,000 | $624,000 | 0.02% | -850,000 |
| Larimar Therapeutics Inc. LRMR | 188,102 | $573,711 | 0.02% | -878,858 |
| CG Oncology Inc. CGON | 5,000 | $355,250 | 0.01% | -15,000 |
| Quoin Pharmaceuticals Ltd ADR QNRX | 72,730 | $352,013 | 0.01% | no change |
| Equillium Inc. EQ | 90,000 | $288,000 | 0.01% | new |
| Natera Inc Com NTRA | 1,000 | $271,450 | 0.01% | -118,000 |
| Neogenomics Inc. NEO | 10,000 | $145,900 | 0.01% | -165,000 |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.